Nephrology News
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/